Jun 27, 2022

PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders

Jun 2, 2022

PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive Compounds

May 30, 2022

PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development Milestones

May 16, 2022

PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted Compound

May 6, 2022

PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio Development

Apr 29, 2022

KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing

Apr 27, 2022

PsyBio Therapeutics Begins Filing Global Provisional Patent Conversion Applications to Further Strengthen Biosynthetic Patent Portfolio

Apr 25, 2022

KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th

Apr 19, 2022

PsyBio Therapeutics to Participate in Upcoming Investor Conferences in April 2022

Apr 13, 2022

PsyBio Therapeutics Initiates Clinical Trial Site Selection Process

Mar 23, 2022

PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022

Mar 15, 2022

PsyBio Therapeutics Announces Proposed Acquisition of Everest Pharma (Pty) Ltd., a Lesotho Company in Southern Africa, as Part of Its Ongoing Impact Investment Strategy